nodes	percent_of_prediction	percent_of_DWPC	metapath
Nepafenac—PTGS1—Montelukast—chronic obstructive pulmonary disease	0.563	1	CbGbCtD
Nepafenac—Rheumatoid arthritis—Formoterol—chronic obstructive pulmonary disease	0.0159	0.0458	CcSEcCtD
Nepafenac—Rheumatoid arthritis—Arformoterol—chronic obstructive pulmonary disease	0.0159	0.0458	CcSEcCtD
Nepafenac—Intraocular pressure increased—Tiotropium—chronic obstructive pulmonary disease	0.0135	0.039	CcSEcCtD
Nepafenac—Ulcerative keratitis—Prednisolone—chronic obstructive pulmonary disease	0.0103	0.0297	CcSEcCtD
Nepafenac—Eye pruritus—Salbutamol—chronic obstructive pulmonary disease	0.0101	0.0292	CcSEcCtD
Nepafenac—Sensation of foreign body—Prednisolone—chronic obstructive pulmonary disease	0.00796	0.023	CcSEcCtD
Nepafenac—Ulcerative keratitis—Prednisone—chronic obstructive pulmonary disease	0.00746	0.0216	CcSEcCtD
Nepafenac—Dermatitis atopic—Montelukast—chronic obstructive pulmonary disease	0.00634	0.0183	CcSEcCtD
Nepafenac—Cataract—Tiotropium—chronic obstructive pulmonary disease	0.00623	0.018	CcSEcCtD
Nepafenac—Impaired healing—Prednisolone—chronic obstructive pulmonary disease	0.006	0.0173	CcSEcCtD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—SCGB1A1—chronic obstructive pulmonary disease	0.00592	0.0948	CbGpPWpGaD
Nepafenac—Intraocular pressure increased—Prednisolone—chronic obstructive pulmonary disease	0.0059	0.017	CcSEcCtD
Nepafenac—Conjunctival hyperaemia—Prednisolone—chronic obstructive pulmonary disease	0.0059	0.017	CcSEcCtD
Nepafenac—Sinusitis—Roflumilast—chronic obstructive pulmonary disease	0.00495	0.0143	CcSEcCtD
Nepafenac—Blood pressure increased—Arformoterol—chronic obstructive pulmonary disease	0.00479	0.0138	CcSEcCtD
Nepafenac—Blood pressure increased—Formoterol—chronic obstructive pulmonary disease	0.00479	0.0138	CcSEcCtD
Nepafenac—PTGS2—Prostaglandin Synthesis and Regulation—SCGB1A1—chronic obstructive pulmonary disease	0.0047	0.0753	CbGpPWpGaD
Nepafenac—Blood pressure increased—Salbutamol—chronic obstructive pulmonary disease	0.00452	0.0131	CcSEcCtD
Nepafenac—Arthritis—Tiotropium—chronic obstructive pulmonary disease	0.00443	0.0128	CcSEcCtD
Nepafenac—Impaired healing—Prednisone—chronic obstructive pulmonary disease	0.00436	0.0126	CcSEcCtD
Nepafenac—Intraocular pressure increased—Prednisone—chronic obstructive pulmonary disease	0.00428	0.0124	CcSEcCtD
Nepafenac—Immune system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00428	0.0124	CcSEcCtD
Nepafenac—Keratitis—Prednisolone—chronic obstructive pulmonary disease	0.004	0.0116	CcSEcCtD
Nepafenac—Endophthalmitis—Prednisone—chronic obstructive pulmonary disease	0.00396	0.0114	CcSEcCtD
Nepafenac—Diabetes mellitus—Salbutamol—chronic obstructive pulmonary disease	0.00377	0.0109	CcSEcCtD
Nepafenac—PTGS2—leg—chronic obstructive pulmonary disease	0.0037	0.311	CbGeAlD
Nepafenac—Arthritis—Arformoterol—chronic obstructive pulmonary disease	0.00358	0.0103	CcSEcCtD
Nepafenac—Arthritis—Formoterol—chronic obstructive pulmonary disease	0.00358	0.0103	CcSEcCtD
Nepafenac—Dermatitis atopic—Prednisolone—chronic obstructive pulmonary disease	0.0035	0.0101	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.00349	0.0101	CcSEcCtD
Nepafenac—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.0033	0.00954	CcSEcCtD
Nepafenac—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.00327	0.00945	CcSEcCtD
Nepafenac—Sinusitis—Tiotropium—chronic obstructive pulmonary disease	0.00311	0.009	CcSEcCtD
Nepafenac—Eye irritation—Prednisolone—chronic obstructive pulmonary disease	0.00304	0.00878	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00291	0.0084	CcSEcCtD
Nepafenac—Eye disorder—Tiotropium—chronic obstructive pulmonary disease	0.00278	0.00805	CcSEcCtD
Nepafenac—Angiopathy—Tiotropium—chronic obstructive pulmonary disease	0.0027	0.00781	CcSEcCtD
Nepafenac—Diclofenac—CXCL8—chronic obstructive pulmonary disease	0.00269	0.158	CrCbGaD
Nepafenac—Immune system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00269	0.00778	CcSEcCtD
Nepafenac—Mebendazole—CYP1A1—chronic obstructive pulmonary disease	0.00257	0.151	CrCbGaD
Nepafenac—Dermatitis atopic—Prednisone—chronic obstructive pulmonary disease	0.00255	0.00736	CcSEcCtD
Nepafenac—Sinusitis—Arformoterol—chronic obstructive pulmonary disease	0.00251	0.00726	CcSEcCtD
Nepafenac—Sinusitis—Formoterol—chronic obstructive pulmonary disease	0.00251	0.00726	CcSEcCtD
Nepafenac—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.00248	0.00717	CcSEcCtD
Nepafenac—Sinusitis—Montelukast—chronic obstructive pulmonary disease	0.00246	0.00711	CcSEcCtD
Nepafenac—Vision blurred—Tiotropium—chronic obstructive pulmonary disease	0.00244	0.00706	CcSEcCtD
Nepafenac—Ketoprofen—CXCL8—chronic obstructive pulmonary disease	0.00238	0.14	CrCbGaD
Nepafenac—Sinusitis—Salbutamol—chronic obstructive pulmonary disease	0.00237	0.00686	CcSEcCtD
Nepafenac—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.00224	0.00647	CcSEcCtD
Nepafenac—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00223	0.00643	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—HMOX1—chronic obstructive pulmonary disease	0.00221	0.0354	CbGpPWpGaD
Nepafenac—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.0022	0.00636	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00219	0.00634	CcSEcCtD
Nepafenac—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.00217	0.00628	CcSEcCtD
Nepafenac—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00217	0.00628	CcSEcCtD
Nepafenac—Diabetes mellitus—Prednisolone—chronic obstructive pulmonary disease	0.00216	0.00625	CcSEcCtD
Nepafenac—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.00216	0.00624	CcSEcCtD
Nepafenac—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00214	0.00619	CcSEcCtD
Nepafenac—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.00213	0.00615	CcSEcCtD
Nepafenac—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00211	0.00609	CcSEcCtD
Nepafenac—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00208	0.006	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—ELANE—chronic obstructive pulmonary disease	0.00206	0.033	CbGpPWpGaD
Nepafenac—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.00206	0.00595	CcSEcCtD
Nepafenac—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00206	0.00594	CcSEcCtD
Nepafenac—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00205	0.00593	CcSEcCtD
Nepafenac—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.002	0.00578	CcSEcCtD
Nepafenac—Cataract—Prednisone—chronic obstructive pulmonary disease	0.00198	0.00572	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00183	0.00528	CcSEcCtD
Nepafenac—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.00181	0.00522	CcSEcCtD
Nepafenac—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.00181	0.00522	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00177	0.00512	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00177	0.00512	CcSEcCtD
Nepafenac—PTGS2—Overview of nanoparticle effects—HMOX1—chronic obstructive pulmonary disease	0.00175	0.0281	CbGpPWpGaD
Nepafenac—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00174	0.00504	CcSEcCtD
Nepafenac—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00174	0.00504	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00173	0.00501	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—CRP—chronic obstructive pulmonary disease	0.00173	0.0277	CbGpPWpGaD
Nepafenac—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.00171	0.00493	CcSEcCtD
Nepafenac—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00168	0.00484	CcSEcCtD
Nepafenac—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00168	0.00484	CcSEcCtD
Nepafenac—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00166	0.0048	CcSEcCtD
Nepafenac—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00166	0.0048	CcSEcCtD
Nepafenac—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00165	0.00478	CcSEcCtD
Nepafenac—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.00165	0.00476	CcSEcCtD
Nepafenac—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00164	0.00474	CcSEcCtD
Nepafenac—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00163	0.0047	CcSEcCtD
Nepafenac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—chronic obstructive pulmonary disease	0.00159	0.0255	CbGpPWpGaD
Nepafenac—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00159	0.00459	CcSEcCtD
Nepafenac—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00158	0.00457	CcSEcCtD
Nepafenac—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.00157	0.00455	CcSEcCtD
Nepafenac—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00157	0.00453	CcSEcCtD
Nepafenac—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.00156	0.00451	CcSEcCtD
Nepafenac—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.0015	0.00433	CcSEcCtD
Nepafenac—Magnesium salicylate—ALB—chronic obstructive pulmonary disease	0.00149	0.0877	CrCbGaD
Nepafenac—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00148	0.00429	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00148	0.00426	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00148	0.00426	CcSEcCtD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—EDN1—chronic obstructive pulmonary disease	0.00145	0.0231	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00144	0.00418	CcSEcCtD
Nepafenac—PTGS1—Selenium Micronutrient Network—SOD3—chronic obstructive pulmonary disease	0.00144	0.023	CbGpPWpGaD
Nepafenac—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00143	0.00412	CcSEcCtD
Nepafenac—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00141	0.00406	CcSEcCtD
Nepafenac—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.0014	0.00405	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00139	0.00402	CcSEcCtD
Nepafenac—PTGS2—Overview of nanoparticle effects—CRP—chronic obstructive pulmonary disease	0.00137	0.022	CbGpPWpGaD
Nepafenac—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00135	0.00389	CcSEcCtD
Nepafenac—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00133	0.00385	CcSEcCtD
Nepafenac—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00133	0.00383	CcSEcCtD
Nepafenac—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00126	0.00364	CcSEcCtD
Nepafenac—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00126	0.00364	CcSEcCtD
Nepafenac—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00126	0.00363	CcSEcCtD
Nepafenac—Diclofenac—CYP1A1—chronic obstructive pulmonary disease	0.00126	0.0737	CrCbGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.00125	0.02	CbGpPWpGaD
Nepafenac—PTGS1—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00124	0.0198	CbGpPWpGaD
Nepafenac—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.00123	0.00356	CcSEcCtD
Nepafenac—Diclofenac—CYP1A2—chronic obstructive pulmonary disease	0.00121	0.0711	CrCbGaD
Nepafenac—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00121	0.00349	CcSEcCtD
Nepafenac—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00121	0.00349	CcSEcCtD
Nepafenac—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.00119	0.00343	CcSEcCtD
Nepafenac—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00118	0.00342	CcSEcCtD
Nepafenac—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—chronic obstructive pulmonary disease	0.00115	0.0184	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—SOD3—chronic obstructive pulmonary disease	0.00114	0.0183	CbGpPWpGaD
Nepafenac—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.00114	0.0033	CcSEcCtD
Nepafenac—Modafinil—CYP1A2—chronic obstructive pulmonary disease	0.00114	0.0668	CrCbGaD
Nepafenac—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00113	0.00327	CcSEcCtD
Nepafenac—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00113	0.00327	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—CXCL8—chronic obstructive pulmonary disease	0.00113	0.018	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—MMP12—chronic obstructive pulmonary disease	0.00112	0.0179	CbGpPWpGaD
Nepafenac—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00111	0.0032	CcSEcCtD
Nepafenac—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00109	0.00314	CcSEcCtD
Nepafenac—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00109	0.00314	CcSEcCtD
Nepafenac—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00107	0.00309	CcSEcCtD
Nepafenac—Headache—Formoterol—chronic obstructive pulmonary disease	0.00107	0.00309	CcSEcCtD
Nepafenac—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.00107	0.00309	CcSEcCtD
Nepafenac—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00107	0.00308	CcSEcCtD
Nepafenac—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.00106	0.00307	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—CYP1A2—chronic obstructive pulmonary disease	0.00105	0.0168	CbGpPWpGaD
Nepafenac—Fenoprofen—ALB—chronic obstructive pulmonary disease	0.00105	0.0616	CrCbGaD
Nepafenac—Headache—Montelukast—chronic obstructive pulmonary disease	0.00105	0.00303	CcSEcCtD
Nepafenac—Carbamazepine—CYP1A2—chronic obstructive pulmonary disease	0.00104	0.061	CrCbGaD
Nepafenac—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00103	0.00296	CcSEcCtD
Nepafenac—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00101	0.00293	CcSEcCtD
Nepafenac—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00101	0.00293	CcSEcCtD
Nepafenac—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00101	0.00292	CcSEcCtD
Nepafenac—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000994	0.00287	CcSEcCtD
Nepafenac—PTGS2—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000983	0.0157	CbGpPWpGaD
Nepafenac—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000979	0.00283	CcSEcCtD
Nepafenac—PTGS1—Selenium Micronutrient Network—MPO—chronic obstructive pulmonary disease	0.000965	0.0155	CbGpPWpGaD
Nepafenac—PTGS1—respiratory system—chronic obstructive pulmonary disease	0.000963	0.0808	CbGeAlD
Nepafenac—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000958	0.00277	CcSEcCtD
Nepafenac—PTGS2—respiratory system—chronic obstructive pulmonary disease	0.00092	0.0773	CbGeAlD
Nepafenac—PTGS1—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.0009	0.0144	CbGpPWpGaD
Nepafenac—PTGS2—Overview of nanoparticle effects—CXCL8—chronic obstructive pulmonary disease	0.000893	0.0143	CbGpPWpGaD
Nepafenac—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000884	0.00256	CcSEcCtD
Nepafenac—Oxcarbazepine—ALB—chronic obstructive pulmonary disease	0.000881	0.0517	CrCbGaD
Nepafenac—PTGS1—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000868	0.0139	CbGpPWpGaD
Nepafenac—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000859	0.00248	CcSEcCtD
Nepafenac—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000855	0.00247	CcSEcCtD
Nepafenac—PTGS1—connective tissue—chronic obstructive pulmonary disease	0.000848	0.0711	CbGeAlD
Nepafenac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—chronic obstructive pulmonary disease	0.000833	0.0133	CbGpPWpGaD
Nepafenac—PTGS2—connective tissue—chronic obstructive pulmonary disease	0.00081	0.068	CbGeAlD
Nepafenac—PTGS2—C-MYB transcription factor network—MPO—chronic obstructive pulmonary disease	0.000795	0.0127	CbGpPWpGaD
Nepafenac—PTGS1—Overview of nanoparticle effects—TNF—chronic obstructive pulmonary disease	0.000783	0.0125	CbGpPWpGaD
Nepafenac—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000776	0.00224	CcSEcCtD
Nepafenac—PTGS1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000775	0.0651	CbGeAlD
Nepafenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—chronic obstructive pulmonary disease	0.000769	0.0123	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—MPO—chronic obstructive pulmonary disease	0.000766	0.0123	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	0.000764	0.0122	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000762	0.0122	CbGpPWpGaD
Nepafenac—PTGS2—bronchus—chronic obstructive pulmonary disease	0.000757	0.0636	CbGeAlD
Nepafenac—PTGS2—smooth muscle tissue—chronic obstructive pulmonary disease	0.000741	0.0622	CbGeAlD
Nepafenac—PTGS2—S1P1 pathway—VEGFA—chronic obstructive pulmonary disease	0.000726	0.0116	CbGpPWpGaD
Nepafenac—PTGS2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000714	0.0114	CbGpPWpGaD
Nepafenac—PTGS1—trachea—chronic obstructive pulmonary disease	0.000712	0.0597	CbGeAlD
Nepafenac—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000711	0.00206	CcSEcCtD
Nepafenac—Diclofenac—ALB—chronic obstructive pulmonary disease	0.0007	0.0411	CrCbGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000697	0.00201	CcSEcCtD
Nepafenac—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000682	0.00197	CcSEcCtD
Nepafenac—PTGS2—trachea—chronic obstructive pulmonary disease	0.00068	0.0571	CbGeAlD
Nepafenac—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000659	0.00191	CcSEcCtD
Nepafenac—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000653	0.00189	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—IL6—chronic obstructive pulmonary disease	0.000632	0.0101	CbGpPWpGaD
Nepafenac—PTGS1—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00063	0.0101	CbGpPWpGaD
Nepafenac—PTGS2—Overview of nanoparticle effects—TNF—chronic obstructive pulmonary disease	0.000622	0.00996	CbGpPWpGaD
Nepafenac—Ketoprofen—ALB—chronic obstructive pulmonary disease	0.00062	0.0364	CrCbGaD
Nepafenac—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000612	0.00177	CcSEcCtD
Nepafenac—Headache—Prednisolone—chronic obstructive pulmonary disease	0.00058	0.00168	CcSEcCtD
Nepafenac—PTGS1—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000555	0.00888	CbGpPWpGaD
Nepafenac—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.00055	0.00159	CcSEcCtD
Nepafenac—PTGS1—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000548	0.00878	CbGpPWpGaD
Nepafenac—PTGS1—lung—chronic obstructive pulmonary disease	0.000511	0.0429	CbGeAlD
Nepafenac—PTGS1—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	0.000508	0.00813	CbGpPWpGaD
Nepafenac—PTGS2—Overview of nanoparticle effects—IL6—chronic obstructive pulmonary disease	0.000502	0.00804	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—GSTM1—chronic obstructive pulmonary disease	0.000498	0.00797	CbGpPWpGaD
Nepafenac—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000495	0.00143	CcSEcCtD
Nepafenac—PTGS2—lung—chronic obstructive pulmonary disease	0.000489	0.041	CbGeAlD
Nepafenac—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000476	0.00137	CcSEcCtD
Nepafenac—PTGS1—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000461	0.00738	CbGpPWpGaD
Nepafenac—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000445	0.00128	CcSEcCtD
Nepafenac—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000428	0.00124	CcSEcCtD
Nepafenac—Headache—Prednisone—chronic obstructive pulmonary disease	0.000421	0.00122	CcSEcCtD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—chronic obstructive pulmonary disease	0.000412	0.0066	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	0.000403	0.00646	CbGpPWpGaD
Nepafenac—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000399	0.00115	CcSEcCtD
Nepafenac—PTGS1—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	0.00039	0.00624	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.00039	0.00624	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—ALB—chronic obstructive pulmonary disease	0.000389	0.00623	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000384	0.00616	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	0.000358	0.00573	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000353	0.00566	CbGpPWpGaD
Nepafenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—chronic obstructive pulmonary disease	0.000336	0.00539	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000335	0.00536	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	0.000322	0.00516	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	0.000317	0.00507	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—LEP—chronic obstructive pulmonary disease	0.000312	0.005	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	0.00031	0.00496	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000309	0.00496	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—ALB—chronic obstructive pulmonary disease	0.000309	0.00495	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	0.000307	0.00491	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TLR4—chronic obstructive pulmonary disease	0.000306	0.00489	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—NOS2—chronic obstructive pulmonary disease	0.000291	0.00466	CbGpPWpGaD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—chronic obstructive pulmonary disease	0.000287	0.00459	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—APIP—chronic obstructive pulmonary disease	0.000269	0.00432	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	0.000251	0.00403	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	0.00023	0.00368	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—APIP—chronic obstructive pulmonary disease	0.000214	0.00343	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—CXCL8—chronic obstructive pulmonary disease	0.000207	0.00332	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IL1B—chronic obstructive pulmonary disease	0.000199	0.00318	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	0.000192	0.00308	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—MMP9—chronic obstructive pulmonary disease	0.000187	0.003	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	0.000185	0.00297	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	0.000182	0.00292	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000178	0.00286	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	0.000177	0.00283	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GC—chronic obstructive pulmonary disease	0.000174	0.00278	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000161	0.00259	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TGFB1—chronic obstructive pulmonary disease	0.000155	0.00247	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	0.000153	0.00244	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—EGFR—chronic obstructive pulmonary disease	0.000152	0.00243	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	0.000147	0.00236	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TNF—chronic obstructive pulmonary disease	0.000144	0.00231	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000142	0.00227	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	0.000141	0.00225	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GC—chronic obstructive pulmonary disease	0.000138	0.00221	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	0.000129	0.00206	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000128	0.00205	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TP53—chronic obstructive pulmonary disease	0.000127	0.00204	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IL6—chronic obstructive pulmonary disease	0.000116	0.00186	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	0.000115	0.00183	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	0.000105	0.00168	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	0.000103	0.00165	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	0.000102	0.00164	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	9.82e-05	0.00157	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.49e-05	0.00152	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GCLC—chronic obstructive pulmonary disease	9.38e-05	0.0015	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.74e-05	0.0014	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	8.65e-05	0.00139	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CTGF—chronic obstructive pulmonary disease	8.56e-05	0.00137	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.88e-05	0.00126	CbGpPWpGaD
Nepafenac—PTGS2—Disease—HDAC2—chronic obstructive pulmonary disease	7.56e-05	0.00121	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.53e-05	0.00121	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GCLC—chronic obstructive pulmonary disease	7.44e-05	0.00119	CbGpPWpGaD
Nepafenac—PTGS2—Disease—KL—chronic obstructive pulmonary disease	7.03e-05	0.00113	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.94e-05	0.00111	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CTGF—chronic obstructive pulmonary disease	6.79e-05	0.00109	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.57e-05	0.00105	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.48e-05	0.00104	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.26e-05	0.001	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.04e-05	0.000968	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.73e-05	0.000917	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ERBB3—chronic obstructive pulmonary disease	5.27e-05	0.000843	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.22e-05	0.000836	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.15e-05	0.000824	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.8e-05	0.000768	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.55e-05	0.000728	CbGpPWpGaD
Nepafenac—PTGS2—Disease—NOS2—chronic obstructive pulmonary disease	4.39e-05	0.000703	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ALB—chronic obstructive pulmonary disease	3.89e-05	0.000624	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.72e-05	0.000596	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SERPINE1—chronic obstructive pulmonary disease	3.7e-05	0.000592	CbGpPWpGaD
Nepafenac—PTGS2—Disease—NOS3—chronic obstructive pulmonary disease	3.53e-05	0.000565	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ALB—chronic obstructive pulmonary disease	3.09e-05	0.000495	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.96e-05	0.000473	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TGFB1—chronic obstructive pulmonary disease	2.33e-05	0.000374	CbGpPWpGaD
Nepafenac—PTGS2—Disease—EGFR—chronic obstructive pulmonary disease	2.29e-05	0.000367	CbGpPWpGaD
Nepafenac—PTGS2—Disease—IL6—chronic obstructive pulmonary disease	1.76e-05	0.000282	CbGpPWpGaD
